Saratov JOURNAL of Medical and Scientific Research

The prospects for application of biomarker "vascular endothelial growth factor" in predicting the treatment outcomes of bladder cancer

Year: 2018, volume 14 Issue: №2 Pages: 268-272
Heading: Urology Article type: Original article
Authors: Zakharova N.B., Ponukalin A.N., Skriptsova S.A.
Organization: Saratov State Medical University

Purpose: assessment of the diagnostic value of Vascular Endothelial Growth Factor (VEGF) in predicting the outcome treatment of patients with muscle-invasive bladder cancer. Material and Methods. The study involved 264 people: 204 patients with RMP; 60 people aged 21 to 60 years were the comparison group. Patients with RMP are divided into stages of the disease. With non-muscle-invasive ВС (NIRMP) under TA-1NxMo there were 75 patients. Out of 129 patients with muscle-invasive ВС (MIRE) within the body (pT2aN0M0-T2bN0M0) was diagnosed in 69 of people. In 60 patients, the tumor sprouted paravesical tissue and surrounding organs (rt3a-bn0m0-41; pT36N1M0-11; pT4N1M0-5; T4N1M1-3); 19 patients had metastases to the iliac lymph nodes are installed only after the operation. Metastases were found in three patients out of 19 in addition to the lymphonoduses in the lungs. Tumors had the following gradations: G1-97; G2-37; G3-58. All patients NMIN (n=75) completed a TUR of the bladder wall with the tumor. MERE patients underwent radical cystectomy (n=117), open resection of the bladder (n=12), palliative surgery (n=3). The period of follow-up after surgical treatment was 3.5±0.5years. Quantitative determination of VEGF in blood serum was performed by solid-phase ELISA. Results. Despite the fact that the increase in VEGF level of blood serum in groups of patients with NIMRE and MIRE has significant differences both before and in the postoperative period, it is associated with the aggressiveness of tumor growth, development of metastases and recurrences of the disease. Conclusion. The increase in the content of VEGF serum suitable for use as an indicator: the risk of relapse within the first year after TUR in patients NMIN; development of relapses and metastases in pre and postoperative periods in MERE patients.

1. Kaprin AD, Starinskiy VV, Petrova GV, eds. State of cancer care in Russia in 2015. Moscow, 2016; 236 p.
2. Apolikhin Ol, Sivkov AV, Moskalyeva NG, et al. Analysis of urological and nephrological morbidity and lethality in Russian Federation in 2010-2011. Experimental and Clinical Urology 2013; (2): 10-7
3. Matveyev ВР, ed. Clinical Oncourology. Moscow, 2011; 357 p.
4. Clinical Recommendations of European Urological Association, 2014, 968 p.
5. Massari F, Santoni М, Ciccarese С, et al. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Crit Rev Oncol Hematol 2015; 96: 81-90
6. Glybochko PV, Shahpazyan NK, Ponukalin AN, Zakharo-va NB. Molecular markers in diagnostics of non-muscle-invasive bladder cancer. Clinical Laboratory Diagnostics 2011; (5): 16-20
7. Ponukalin AN, Popkov VM.Zakharova NB, Mikhaylov VYu. Oncologic markers in diagnostics of the stage of bladder cancer invasion. Bashkortostan Medical Bulletin 2013; 8 (2): 213-7
8. Fernandez-Gomez J, Solsona Е, Unda М, et al. Prognostic factors in patients with nonmuscle-invasive bladder cancer treated with Bacillus Calmette — Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 992-1002
9. Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature Med 2010; 407: 249-57
10. Folkman J. Is angiogenesis an organizing principle in biology and medicine? J Pediat Surg 2007; 42 (1): 1-11
11. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-8
12. Mnikhovich MV, Gershzon D, Brickman Ml, et al. Morphological and genetic mechanisms of cell interaction in angiogenesis. Journal of Anatomy and Histopathology 2012; 1 (3): 63-5
13. Spirina LV, Kondakova IV, Usynin ЕА, et al. Proteasome activity and growth factors content in kidney, bladder and endo-metrial cancer. Russian Journal of Oncology 2010; (1): 23-5
14. Kharchenko ЕР. Carcinogenesis: immune system and immunotherapy. Immunology 2011; 32 (1): 50-6
15. Li С, Liu В, Dai Z, Tao Y. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and rowth of clear cell renal cell carcinoma (CRCC). Cancer Biol Ther 2011 ;12 (10): 872-80
16. Behnes CL, Bremmer F, Hemmerlein B, et al. Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma. Virchows Arch 2014; 464 (2): 191-6
17. Franklin RA, Liao W, SarkarA, et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014; 344:921-5
18. Spirina LV, Usynin EA, Kondakova IV, et al. Influence of targeted therapy on molecular tumor markers in patients with disseminated kidney cancer. Advances in Molecular Oncology 2015; 2 (4): 83-84
19. Luo Y, Askeland EJ, Newton MR, et al. Immunotherapy of Urinary Bladder Carcinoma: BCG and Beyond, 2013; p. 319-57 (Chapter 15)
20. Popkov VM, PonukalinAN.ZakharovaNB. Vascularendo-thelial growth factor in the diagnosis of metastases of muscle-invasive bladder cancer. Oncourology 2016; 12 (2): 53-7
21. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6
22. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 408-16
23. Folkman J. The vascularization of tumors. Sci Am 1976; 234: 58-73
24. Zakharova NB, Varaksin NA, Tereshkina NE, et al. The concentration of vascular endothelial growth factor in the blood of healthy individuals depends on the age. News Vector-Best: Newsletter 2014; 71 (1): 11-15.

2018_2_268-272.pdf242.72 KB

No votes yet